{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:48:58Z","timestamp":1792259338209,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010941","name":"University of Vermont","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prro.2025.10.010","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:49:58Z","timestamp":1763502598000},"page":"119-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline"],"prefix":"10.1016","volume":"16","author":[{"given":"Christopher J.","family":"Anker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Dehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Haustermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma K.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila T.","family":"Tchelebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Willett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.10.010_bib0001","series-title":"Clinical Practice Guidelines We Can Trust","article-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"key":"10.1016\/j.prro.2025.10.010_bib0002","series-title":"Finding What Works In Health Care: Standards for Systematic Reviews","article-title":"Committee on Standards for Systematic Reviews of Comparative Effectiveness","year":"2011"},{"key":"10.1016\/j.prro.2025.10.010_bib0003","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2025.10.010_bib0004","article-title":"Gastric cancer-Epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: An updated review","volume":"41","author":"Mamun","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.prro.2025.10.010_bib0005","first-page":"1586","article-title":"Gender differences in gastric cancer: Molecular and epidemiological perspectives","volume":"12","author":"Seo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prro.2025.10.010_bib0006","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: stomach cancer. 2025. Accessed June 1, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"key":"10.1016\/j.prro.2025.10.010_bib0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5230\/jgc.2022.22.e21","article-title":"Epidemiology of gastric cancer in Korea: Trends in incidence and survival based on Korea Central Cancer Registry data (1999\u20132019)","volume":"22","author":"Park","year":"2022","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0008","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/1097-0142(20001201)89:11<2237::AID-CNCR12>3.0.CO;2-9","article-title":"Is gastric carcinoma different between Japan and the United States?","volume":"89","author":"Noguchi","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.prro.2025.10.010_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.prro.2025.10.010_bib0011","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0012","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.10.010_bib0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.10.010_bib0014","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.10.010_bib0016","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"10.1016\/j.prro.2025.10.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0018","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2022.06.012","article-title":"Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study","volume":"173","author":"Kroese","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0019","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","article-title":"Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis","volume":"166","author":"Kroese","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220771","article-title":"Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: Outcome and prognostic factors","volume":"96","author":"Franceschini","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.10.010_bib0021","first-page":"109","article-title":"Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study","volume":"37","author":"Kroese","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0022","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/ijc.35111","article-title":"Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal\/GEJ cancer","volume":"155","author":"Noronha","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0023","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.10.010_bib0025","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1245\/s10434-017-5830-6","article-title":"TOPGEAR: A randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG","volume":"24","author":"Leong","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0026","article-title":"Preoperative concurrent chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: Phase II randomized study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20201088","article-title":"Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study","volume":"94","author":"Wang","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.10.010_bib0028","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2025.10.010_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0030","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0031","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.10.010_bib0033","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","article-title":"Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0034","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1245\/s10434-021-11050-6","article-title":"Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: Systematic review and meta-analysis","volume":"29","author":"Nie","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: The ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0036","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0037","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","article-title":"Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in stage III gastric cancer: A final report of the JACCRO GC-07 study","volume":"26","author":"Kodera","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0038","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): An open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0039","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","article-title":"Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): An open-label, phase 3, non-inferiority, randomised trial","volume":"4","author":"Yoshikawa","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2025.10.010_bib0040","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-010-1256-6","article-title":"A randomized phase III study of adjuvant platinum\/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer","volume":"65","author":"Bamias","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.prro.2025.10.010_bib0041","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000292360","article-title":"Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: A phase III randomized, multicenter, clinical trial","volume":"78","author":"Kulig","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.prro.2025.10.010_bib0042","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0043","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0044","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.radonc.2012.08.024","article-title":"A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection","volume":"104","author":"Zhu","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0045","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.2017.74.2130","article-title":"Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: Results from CALGB 80101 (Alliance)","volume":"35","author":"Fuchs","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0046","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1097\/JS9.0000000000000692","article-title":"Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: Long-term results of a phase III randomized controlled trial","volume":"109","author":"Tian","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.prro.2025.10.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0426","article-title":"Effect of S-1 plus oxaliplatin compared with fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: A randomized clinical trial","volume":"5","author":"Yu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.prro.2025.10.010_bib0048","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.10.010_bib0049","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/PL00011681","article-title":"Japanese Classification of Gastric Carcinoma - 2nd English Edition","volume":"1","year":"1998","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0051","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0052","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijrobp.2017.03.032","article-title":"Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer","volume":"98","author":"Liu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.10.010_bib0053","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3892\/mco.2014.348","article-title":"Radiotherapy and chemoradiotherapy as a novel option for the treatment of locally advanced inoperable gastric adenocarcinoma: A phase II study","volume":"2","author":"Wydmanski","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0054","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5301\/tj.5000336","article-title":"Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence","volume":"101","author":"Xie","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.prro.2025.10.010_bib0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/COC.0b013e31828f5cb6","article-title":"Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence","volume":"38","author":"Yuan","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0056","doi-asserted-by":"crossref","first-page":"13339","DOI":"10.2147\/CMAR.S280225","article-title":"Radiotherapy combined with chemotherapy for regional lymph node recurrence in gastric cancer","volume":"12","author":"Cai","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.prro.2025.10.010_bib0057","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.6061\/clinics\/2020\/e1644","article-title":"Palliative radiotherapy for gastric cancer: Is there a dose relationship between bleeding response and radiotherapy?","volume":"75","author":"Viani","year":"2020","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.prro.2025.10.010_bib0058","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/j.clon.2022.05.009","article-title":"Temporal profiles of symptom scores after palliative radiotherapy for bleeding gastric cancer with adjustment for the palliative prognostic index: An exploratory analysis of a multicentre prospective observational study (JROSG 17-3)","volume":"34","author":"Kawamoto","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2025.10.010_bib0059","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190958","article-title":"Hemostatic radiotherapy for inoperable gastric cancer: A pilot study","volume":"93","author":"Tanaka","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.10.010_bib0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.25259\/IJPC_1_2023","article-title":"Bleeding control in advanced gastric cancer; role of radiotherapy","volume":"29","author":"Andleeb","year":"2023","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.prro.2025.10.010_bib0061","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10120-021-01254-w","article-title":"Treatment response after palliative radiotherapy for bleeding gastric cancer: A multicenter prospective observational study (JROSG 17-3)","volume":"25","author":"Saito","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0062","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13014-021-01884-5","article-title":"Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0063","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s12885-021-08145-4","article-title":"Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer","volume":"21","author":"Yu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0064","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/MD.0000000000000118","article-title":"Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era","volume":"93","author":"Tey","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.prro.2025.10.010_bib0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12904-022-00943-2","article-title":"Palliative radiotherapy for gastric cancer bleeding: A multi-institutional retrospective study","volume":"21","author":"Takeda","year":"2022","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.prro.2025.10.010_bib0066","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/cam4.2021","article-title":"Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial","volume":"8","author":"Tey","year":"2019","journal-title":"Cancer Med"},{"issue":"Suppl","key":"10.1016\/j.prro.2025.10.010_bib0067","first-page":"267","article-title":"Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence","volume":"10","author":"Xu","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.prro.2025.10.010_bib0068","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4143\/crt.2014.174","article-title":"Palliative radiotherapy in the presence of well-controlled metastatic disease after initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer","volume":"47","author":"Hingorani","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.prro.2025.10.010_bib0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13014-023-02269-6","article-title":"Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: Data from a phase III clinical trial","volume":"18","author":"Wang","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0071","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2015.08.009","article-title":"Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial","volume":"117","author":"Yu","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0072","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.annonc.2019.10.019","volume":"31","author":"Barbour","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0073","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2007.10.030","article-title":"Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy","volume":"71","author":"Reed","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.10.010_bib0074","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1002\/cam4.3085","article-title":"Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy","volume":"9","author":"Xu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2025.10.010_bib0075","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.2147\/OTT.S177315","article-title":"Patterns of regional nodal relapse after D2 lymphadenectomy in gastric cancer: Rethinking the target volume","volume":"11","author":"Yang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.prro.2025.10.010_bib0076","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2018.07.002","article-title":"Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer","volume":"129","author":"Yu","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0077","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijrobp.2023.06.011","article-title":"The feasibility of quality assurance in the TOPGEAR international phase 3 clinical trial of neoadjuvant chemoradiation therapy for gastric cancer (an intergroup trial of the AGITG\/TROG\/NHMRC CTC\/EORTC\/CCTG)","volume":"117","author":"Lukovic","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.10.010_bib0078","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10120-015-0461-8","article-title":"A phase II trial of concurrent 3D-CRT\/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection","volume":"19","author":"Wang","year":"2016","journal-title":"Gastric Cancer"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.10.010_bib0079","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.10.010_bib0080","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.10.010_bib0081","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.10.010_bib0082","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","article-title":"Radiation dose-volume effects in the spinal cord","volume":"76","author":"Kirkpatrick","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.10.010_bib0083","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","article-title":"Radiation-associated kidney injury","volume":"76","author":"Dawson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.10.010_bib0084","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2020.06.005","article-title":"Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03)","volume":"137","author":"Athauda","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2022.06.025","article-title":"Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts","volume":"173","author":"Quaas","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114043","article-title":"Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials","volume":"203","author":"Raimondi","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0087","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/jso.27554","article-title":"The impact of sex on treatment and outcome in relation to histological subtype in patients with resectable gastric cancer: Results from the randomized CRITICS trial","volume":"129","author":"Caspers","year":"2024","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0088","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2020.02.008","article-title":"Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial","volume":"130","author":"Slagter","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0089","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s10120-021-01228-y","article-title":"Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials","volume":"24","author":"Tsuburaya","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prro.2025.10.010_bib0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4143\/crt.2016.054","article-title":"Adjuvant chemotherapy for advanced gastric cancer in elderly and non-elderly patients: Meta-analysis of randomized controlled trials","volume":"49","author":"Chang","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.prro.2025.10.010_bib0091","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4251\/wjgo.v11.i12.1151","article-title":"Asian Americans have better outcomes of non-metastatic gastric cancer compared to other United States racial groups: A secondary analysis from a randomized study","volume":"11","author":"Abdel-Rahman","year":"2019","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.prro.2025.10.010_bib0092","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.prro.2025.10.010_bib0093","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187985002500270X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187985002500270X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:22:57Z","timestamp":1780039377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187985002500270X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S187985002500270X"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.10.010","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}